Immunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatment

Autores
de Matos, Djamile Cordeiro; Abreu de Ribeiro, Livia Carolina; Tansini, Aline; Ferreira, Lucas Souza; Polesi Placeres, Marisa Campos; Colombo, Lucas Luis; Iracilda Zeppone, Carlos
Año de publicación
2012
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: Ribosome-inactivating proteins (RIP) have been studied in the search for toxins that could be used as immunotoxins for cancer treatment. Pulchellin, a type 2 RIP, is suggested to induce immune responses that have a role in controlling cancer. Methods: The percentage of dendritic cells and CD4+ and CD8+ T cells in the spleen (flow cytometry), cytokines’ release by PECs and splenocytes (ELISA) and nitric oxide production by PECs (Griess assay) were determined from tumor-bearing mice injected intratumorally with 0.1 ml of pulchellin at 0.75 μg/kg of body weight. Statistical analysis was performed by one-way ANOVA with Tukey’s post hoc test. Results: Pulchellin-treated mice showed significant immune system activation, characterized by increased release of IFN-γ and Th2 cytokines (IL-4 and IL-10), while IL-6 and TGF-β levels were decreased. There was also an increase in macrophage’s activation, as denoted by the higher percentage of macrophages expressing adhesion and costimulatory molecules (CD54 and CD80, respectively). Conclusions: Our results suggest that pulchellin is promising as an adjuvant in breast cancer treatment.
Fil: de Matos, Djamile Cordeiro. Universidade de Sao Paulo; Brasil
Fil: Abreu de Ribeiro, Livia Carolina. Universidade de Sao Paulo; Brasil
Fil: Tansini, Aline. Universidade de Sao Paulo; Brasil
Fil: Ferreira, Lucas Souza. Universidade de Sao Paulo; Brasil
Fil: Polesi Placeres, Marisa Campos. Universidade de Sao Paulo; Brasil
Fil: Colombo, Lucas Luis. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Iracilda Zeppone, Carlos. Universidade de Sao Paulo; Brasil
Materia
Pulchellin
Breast cancer,
Cytokines
Immune system
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/107927
Acceder
id CONICETDig_6b0c41395fcc92b9e48d8d7076592d56
oai_identifier_str oai:ri.conicet.gov.ar:11336/107927
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Immunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatmentde Matos, Djamile CordeiroAbreu de Ribeiro, Livia CarolinaTansini, AlineFerreira, Lucas SouzaPolesi Placeres, Marisa CamposColombo, Lucas LuisIracilda Zeppone, CarlosPulchellinBreast cancer,CytokinesImmune systemhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Background: Ribosome-inactivating proteins (RIP) have been studied in the search for toxins that could be used as immunotoxins for cancer treatment. Pulchellin, a type 2 RIP, is suggested to induce immune responses that have a role in controlling cancer. Methods: The percentage of dendritic cells and CD4+ and CD8+ T cells in the spleen (flow cytometry), cytokines’ release by PECs and splenocytes (ELISA) and nitric oxide production by PECs (Griess assay) were determined from tumor-bearing mice injected intratumorally with 0.1 ml of pulchellin at 0.75 μg/kg of body weight. Statistical analysis was performed by one-way ANOVA with Tukey’s post hoc test. Results: Pulchellin-treated mice showed significant immune system activation, characterized by increased release of IFN-γ and Th2 cytokines (IL-4 and IL-10), while IL-6 and TGF-β levels were decreased. There was also an increase in macrophage’s activation, as denoted by the higher percentage of macrophages expressing adhesion and costimulatory molecules (CD54 and CD80, respectively). Conclusions: Our results suggest that pulchellin is promising as an adjuvant in breast cancer treatment.Fil: de Matos, Djamile Cordeiro. Universidade de Sao Paulo; BrasilFil: Abreu de Ribeiro, Livia Carolina. Universidade de Sao Paulo; BrasilFil: Tansini, Aline. Universidade de Sao Paulo; BrasilFil: Ferreira, Lucas Souza. Universidade de Sao Paulo; BrasilFil: Polesi Placeres, Marisa Campos. Universidade de Sao Paulo; BrasilFil: Colombo, Lucas Luis. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Iracilda Zeppone, Carlos. Universidade de Sao Paulo; BrasilBioMed Central2012-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/107927de Matos, Djamile Cordeiro; Abreu de Ribeiro, Livia Carolina; Tansini, Aline; Ferreira, Lucas Souza; Polesi Placeres, Marisa Campos; et al.; Immunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatment; BioMed Central; Bmc Complementary And Alternative Medicine; 12; 1; 7-2012; 1-61472-6882CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://www.biomedcentral.com/1472-6882/12/107info:eu-repo/semantics/altIdentifier/doi/10.1186/1472-6882-12-107info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:55:38Zoai:ri.conicet.gov.ar:11336/107927instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:55:38.806CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Immunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatment
title Immunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatment
spellingShingle Immunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatment
de Matos, Djamile Cordeiro
Pulchellin
Breast cancer,
Cytokines
Immune system
title_short Immunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatment
title_full Immunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatment
title_fullStr Immunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatment
title_full_unstemmed Immunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatment
title_sort Immunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatment
dc.creator.none.fl_str_mv de Matos, Djamile Cordeiro
Abreu de Ribeiro, Livia Carolina
Tansini, Aline
Ferreira, Lucas Souza
Polesi Placeres, Marisa Campos
Colombo, Lucas Luis
Iracilda Zeppone, Carlos
author de Matos, Djamile Cordeiro
author_facet de Matos, Djamile Cordeiro
Abreu de Ribeiro, Livia Carolina
Tansini, Aline
Ferreira, Lucas Souza
Polesi Placeres, Marisa Campos
Colombo, Lucas Luis
Iracilda Zeppone, Carlos
author_role author
author2 Abreu de Ribeiro, Livia Carolina
Tansini, Aline
Ferreira, Lucas Souza
Polesi Placeres, Marisa Campos
Colombo, Lucas Luis
Iracilda Zeppone, Carlos
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Pulchellin
Breast cancer,
Cytokines
Immune system
topic Pulchellin
Breast cancer,
Cytokines
Immune system
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Background: Ribosome-inactivating proteins (RIP) have been studied in the search for toxins that could be used as immunotoxins for cancer treatment. Pulchellin, a type 2 RIP, is suggested to induce immune responses that have a role in controlling cancer. Methods: The percentage of dendritic cells and CD4+ and CD8+ T cells in the spleen (flow cytometry), cytokines’ release by PECs and splenocytes (ELISA) and nitric oxide production by PECs (Griess assay) were determined from tumor-bearing mice injected intratumorally with 0.1 ml of pulchellin at 0.75 μg/kg of body weight. Statistical analysis was performed by one-way ANOVA with Tukey’s post hoc test. Results: Pulchellin-treated mice showed significant immune system activation, characterized by increased release of IFN-γ and Th2 cytokines (IL-4 and IL-10), while IL-6 and TGF-β levels were decreased. There was also an increase in macrophage’s activation, as denoted by the higher percentage of macrophages expressing adhesion and costimulatory molecules (CD54 and CD80, respectively). Conclusions: Our results suggest that pulchellin is promising as an adjuvant in breast cancer treatment.
Fil: de Matos, Djamile Cordeiro. Universidade de Sao Paulo; Brasil
Fil: Abreu de Ribeiro, Livia Carolina. Universidade de Sao Paulo; Brasil
Fil: Tansini, Aline. Universidade de Sao Paulo; Brasil
Fil: Ferreira, Lucas Souza. Universidade de Sao Paulo; Brasil
Fil: Polesi Placeres, Marisa Campos. Universidade de Sao Paulo; Brasil
Fil: Colombo, Lucas Luis. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Iracilda Zeppone, Carlos. Universidade de Sao Paulo; Brasil
description Background: Ribosome-inactivating proteins (RIP) have been studied in the search for toxins that could be used as immunotoxins for cancer treatment. Pulchellin, a type 2 RIP, is suggested to induce immune responses that have a role in controlling cancer. Methods: The percentage of dendritic cells and CD4+ and CD8+ T cells in the spleen (flow cytometry), cytokines’ release by PECs and splenocytes (ELISA) and nitric oxide production by PECs (Griess assay) were determined from tumor-bearing mice injected intratumorally with 0.1 ml of pulchellin at 0.75 μg/kg of body weight. Statistical analysis was performed by one-way ANOVA with Tukey’s post hoc test. Results: Pulchellin-treated mice showed significant immune system activation, characterized by increased release of IFN-γ and Th2 cytokines (IL-4 and IL-10), while IL-6 and TGF-β levels were decreased. There was also an increase in macrophage’s activation, as denoted by the higher percentage of macrophages expressing adhesion and costimulatory molecules (CD54 and CD80, respectively). Conclusions: Our results suggest that pulchellin is promising as an adjuvant in breast cancer treatment.
publishDate 2012
dc.date.none.fl_str_mv 2012-07
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/107927
de Matos, Djamile Cordeiro; Abreu de Ribeiro, Livia Carolina; Tansini, Aline; Ferreira, Lucas Souza; Polesi Placeres, Marisa Campos; et al.; Immunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatment; BioMed Central; Bmc Complementary And Alternative Medicine; 12; 1; 7-2012; 1-6
1472-6882
CONICET Digital
CONICET
url http://hdl.handle.net/11336/107927
identifier_str_mv de Matos, Djamile Cordeiro; Abreu de Ribeiro, Livia Carolina; Tansini, Aline; Ferreira, Lucas Souza; Polesi Placeres, Marisa Campos; et al.; Immunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatment; BioMed Central; Bmc Complementary And Alternative Medicine; 12; 1; 7-2012; 1-6
1472-6882
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.biomedcentral.com/1472-6882/12/107
info:eu-repo/semantics/altIdentifier/doi/10.1186/1472-6882-12-107
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv BioMed Central
publisher.none.fl_str_mv BioMed Central
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269357230522368
score 13.13397

Publicaciones similares